Stoke Therapeutics, Inc. (STOK)
30.54 0.00 (0.00%)
After hours: 4:00PM EDT
Chart Events
Performance Outlook
| Previous Close | 30.91 |
| Open | 31.06 |
| Bid | 30.19 x 900 |
| Ask | 30.36 x 1300 |
| Day's Range | 30.16 - 31.49 |
| 52 Week Range | 19.00 - 71.58 |
| Volume | 269,459 |
| Avg. Volume | 161,635 |
| Market Cap | 1.12B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.66 |
| Earnings Date | Mar 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 68.71 |
- Business Wire
Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2a study (ADMIRAL) of STK-001 for the treatment of Dravet syndrome.
- Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two upcoming investor conferences, which will each be conducted in a fireside chat format:
- Simply Wall St.
We're Not Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
